The growth of solid tumors depends on establishing blood supply; thus, inhibiting tumor angiogenesis has been a long-term goal in cancer therapy. The SOX18 transcription factor is a key regulator of murine and human blood vessel formation. Methods: We established allograft melanoma tumors in wild-type mice, Sox18-null mice, and mice expressing a dominant-negative form of Sox18 (Sox18RaOp) (n = 4 per group) and measured tumor growth and microvessel density by immunohistochemical analysis with antibodies to the endothelial marker CD31 and the pericyte marker NG2. We also assessed the affects of disrupted SOX18 function on MCF-7 human breast cancer and human umbilical vein endothelial cell (HUVEC) proliferation by measuring BrdU incorporation and by MTS assay, cell migration using Boyden chamber assay, and capillary tube formation in vitro. 
developmental angiogenic process ( 4 ) . The signaling pathways that mediate vascular development have been well characterized; endothelial cell tropic factors, such as VEGF, platelet-derived growth factor, fi broblast growth factors, epidermal growth factor, and their receptors, have been identifi ed as key angiogenic regulators ( 5 ) . However, comparatively little is known about the transcriptional regulation of endothelial cell development and function during angiogenesis.
SOX18, a member of the Sry-related HMG box -containing (SOX) family of transcription factors ( 6 ) , is expressed transiently in endothelial cells during the development of all blood vessels in the mouse embryo ( 7 , 8 ) . We have previously shown that SOX18 participates in the VEGF -Flk1 pathway of endothelial cell activation, interacts with the muscle and endothelial transcription factor MEF2C, and activates expression of VCAM1, which is required for endothelial cell function ( 9 , 10 ) . SOX18 binds to the common SOX target sequence (A/T)ACAA(A/T)G and contains a discrete transcriptional transactivation domain ( 11 ) .
The importance of Sox18 for vascular development is revealed by the vascular defects caused by SOX18 mutations in humans and mice. In humans, SOX18 mutations result in hypotrichosislymphedema -telangiectasia syndrome ( 12 ) , characterized by localized vascular leakage and edema. Also, vascular and coat anomalies in ragged (Ra) mutant mice result from mutations in Sox18 ( 13 -15 ) . Among the four allelic forms of Ra, the most s evere phenotype is conferred by ragged-opossum (Ra Op ). Mice heterozygous for this allele show severe vascular and hair follicle anomalies that mimic hypotrichosis -lymphedema -telangiectasia syndrome, and homozygotes die in utero, possibly from gross vascular dysgenesis ( 16 ) . Ra Op mice express a dominant-negative mutant form of Sox18 (Sox18RaOp) that does not interact effectively with the endothelial partner protein MEF2C; this failure to interact blocks angiogenic target gene activation and compromises vascular development ( 9 ) . In contrast, loss of function of Sox18 by gene targeting in mice does not result in a vascular phenotype ( 17 ) , possibly refl ecting genetic redundancy due to the coexpression of the highly related Group F Sox genes Sox7 and Sox17 in developing vasculature ( 18 -20 ) . These fi ndings therefore strongly suggest that the Sox18RaOp mutant protein exerts its dominantnegative effect on SOX7 and SOX17 in addition to SOX18.
Recent studies have shown that all three members of the Group F Sox genes are misexpressed in a variety of human tumor cell lines ( 21 -23 ) . In this study we investigated SOX18 expression in the vasculature of both human and murine tumors, and we tested whether insuffi ciency and/or disruption of Sox18 would restrict neoangiogenesis in and inhibit growth of induced allograft tumors. We also examined the role of SOX18 in endothelial cell differentiation, migration, and proliferation to illuminate the mechanism by which SOX18 might mediate physiologic and pathologic angiogenesis.
M ATERIALS AND M ETHODS

Melanoma Allograft Assay
Six-to 10-week-old wild-type mice on a C57BL/6J background; Sox18 mutant mice from the Ra Op :C57BL/6J strain, obtained from the Jackson Laboratory (Bar Harbor, ME), and mice null for Sox18, on a 129/Sv-CD1 mixed background previously generated in this laboratory ( 17 ) were maintained in-house (University of Queensland). Procedures involving mice and their care conformed to institutional and federal guidelines (University of Queensland Animal Ethics Committee). Mouse B16 melanoma cells (American Type Culture Collection [ATCC], Manassas, VA) (10 6 ) were suspended in phosphate-buffered saline (PBS; 0.2 M sodium phosphate and 0.8% saline, pH 7.2) and were injected bilaterally into the fl anks of mice using a 30-gauge needle (n = 4 mice per strain). Tumor growth was monitored every 48 hours, and tumor volumes were calculated by measuring length and width of each tumor with calipers, according to the Anticancer Drug Development Guide ( 24 ) . Tumor volume data were calculated and graphed as mean tumor volumes and 95% confi dence intervals (CIs). Mice were killed by cervical dislocation at 14 days postgraft or when tumor volumes approached 1000 mm 3 , in accordance with ethical requirements. The experiment was conducted three times. One mouse, heterozygous for the dominantnegative Sox18 mutation Ra O p , from each experiment was maintained for 40 days to ascertain any delayed tumor growth.
In Situ Hybridization Analysis of Sox Gene Expression in Allografts, Human Colorectal Carcinomas, and Mouse Embryos
Human colorectal tumors (n = 4) were supplied from the Royal Brisbane and Women's Hospital in collaboration with Queensland Institute of Medical Research (QIMR). Tumors were collected in accordance with the regulations of University of Queensland Ethics Committee. Mouse allografts (two mice from each strain) were assayed.
Mouse embryos generated from timed 129/Sv-CD1 matings were staged according to the number of tail somites present. To examine Sox expression in endothelial cells lining the posterior dorsal aorta and in the anterior neural medial axial artery, we used stage 9dpc and stage 11.5dpc embryos.
For in situ hybridization, we used standard protocols on multiple samples; in brief, samples were fi xed overnight in 4% paraformaldehyde, dehydrated in methanol, and embedded in wax. Sections (8 mm thick) were mounted serially on Superfrost Plus slides (Lomb Scientifi c, Taren Point, Australia). Slides were dewaxed and hybridized overnight with digoxigenin (DIG)-labeled riboprobes for Sox18, -17, and -7 that were synthesized with the DIG Labeling kit (Roche, Castle Hill, Australia) according to the manufacturer's instructions. Probe primer sequences used were as previously described ( 8 , 20 , 22 ) . Slides were then incubated with antidigoxigenin antibody coupled to alkaline phosphatase (1 : 2500; Roche) until color reaction was seen.
Immunohistologic Analysis of Sox18 Expression
Excised allograft tumors (n = 2 per mouse) were fi xed for 1 hour in 4% paraformaldehyde in PBS, washed overnight in 30% sucrose -PBS, and frozen in compound embedding medium (OCT; Sakura, Tokyo, Japan). Sections (10 μ m thick) were mounted on Superfrost Plus slides. Slides were blocked with 10% heat-inactivated sheep serum (Trace Scientifi c, Clayton, Australia) and 2% bovine serum albumin in PBS and then incubated with mouse monoclonal anti-CD31 (1 : 300; BD-Pharmingen, Palo Alto, CA), mouse monoclonal anti -NG2-Chondroitin (1 : 100; Chemicon, Boronia, Australia), or mouse monoclonal anti-SOX18 (1 : 100; Chemicon) overnight at 4 °C. Slides there then incubated for 1 hour with either Oregon Green-conjugated anti-mouse immunoglobulin G (IgG) or streptavidin-horseradish peroxidase -conjugated polyclonal anti-mouse IgG (1 : 100, Zymed, San Francisco, CA) and examined by fl uorescence microscopy or light microscopy (to visualize the development of diaminobenzidine tetrahydrochloride staining), respectively. Tissues were washed three times with PBS between each step.
Generation of an Adenoviral Vector Overexpressing Sox18
The Sox18 cDNA was excised from pCMV-SPORT6-SOX18 (NIH Mammalian Gene Collection, Bethesda, MD) with Mlu I and subcloned into the Eco RV site of the shuttle vector pAdTrack-CMV (Qbiogene, Carlsbad, CA). Recombinant adenovirus expressing Sox18 was constructed using the pAdEasy system according to the manufacturer's protocol (Qbiogene). Viral titers are reported as log 10 dose giving 50% tissue culture infection per milliliter of culture, and viral particle number was measured at an optical density at 600 nm. Human umbilical vein endothelial cells (HUVECs; ATCC) were isolated and cultured in gelatin-coated fl asks in M199 medium with Earle's balanced salts and 0.68 mM glutamine, 20 mM HEPES, 20% fetal calf serum, 15 μ g/mL endothelial cell growth supplement (BD Biosciences, Bedford, MA), 50 U/mL penicillin, 50 U/mL streptomycin, and 15 μ g/mL heparin (Sigma, St. Louis, MO). For capillary tube formation experiments, HUVECs were grown to 80% confl uence and infected with an amount of pAdEasy empty vector or pAdEasy-Sox18 virus particles to achieve 90% -100% infection effi ciency and that yielded a similar level of green fl uorescence protein expression when measured by fl uorescence-activated cell sorting analysis.
Transient Transfection of HUVECs with Sox18RaOp and Proliferation Assay
HUVECs were grown in human endothelial serum-free medium (Invitrogen, Mt. Waverly, Australia), supplemented with bFGF (20 ng/mL), epidermal growth factor (10 ng/mL), and human plasma fi bronectin (10 μ g/mL). HUVECs were transfected with Sox18, Sox18RaOp-expressing pCDNA3.1 (Invitrogen), or empty vector using Lipofectamine 2000 (Invitrogen) or TransPassD2 reagent (Biolabs), according to the manufacturers' instructions. HUVECs were grown in complete growth medium to 80% confl uence before assays were performed.
For proliferation assays, transfected HUVECs were suspended in complete medium and plated at 4 × 10 3 cells/well in quadruplicate in each of two 96-well plates (one each for day 0 and day 3) and incubated at 37 °C. Soluble tetrazolium salt (MTS) cell viability assays were performed according to the manufacturer's protocol (Promega, Madison, WI) to measure the number of viable cells. In brief, 30 μ L of MTS reagent was added to each well (150 μ L of medium) and incubated at 37 °C for 2 hours. The absorbance at 490 nm was determined on days 0 and 3 using an enzyme-linked immunosorbent assay plate reader.
Matrigel Capillary Tube Formation Assay and Virtual Northern Blot Analysis
Wells of a 96-well fl at-bottom plate were each coated with 100 μ L of Matrigel (Becton Dickinson, Franklin Lakes, NJ), which was allowed to polymerize at 37 °C for 1 hour. HUVECs (4 × 10 4 ) that were infected with pAdEasy empty vector or pAdEasy-Sox18 virus were resuspended in complete medium containing phorbol myristate acetate (20 ng/mL) and anti -α 2 β 1 integrin (30 μ g/mL) and plated on the Matrigel-coated wells. Photographs were taken at regular intervals over 24 hours. Experiments were performed in triplicate.
Virtual northern blot analysis was used to measure Sox18 and cyclophilin (CycA) mRNA expression during capillary tube formation. In brief, total RNA was isolated using TRIzol (Life Technologies, Melbourne, Australia) and reverse transcribed using Omniscript reverse transcriptase (QIAGEN, Valencia, CA). cDNA was amplifi ed quantitatively using the SMART polymerase chain reaction cDNA synthesis procedure using oligo(dT) primers (Clontech, Palo Alto, CA). cDNA was subjected to 0.9% agarose gel electrophoresis and Southern transfer to Hybond-N nylon membranes (Amersham Bioscience, Little Chalfont, St. Giles, UK). We have previously demonstrated the linearity of virtual northern blots for measuring magnitudes of differential gene expression ( 25 ) . Cloned cDNA fragments for Sox18 and CycA (prepared as above) were polymerase chain reaction amplifi ed using T7 and T3 primers and the products labeled with [ α -32 P]dATP using a MegaPrime Kit (Amersham Biosciences). Probes were incubated with membranes at 65 °C for 2 hours in ExpressHyb Hybridization Solution (Clontech), and hybridized DNA was visualized and signals quantifi ed within a linear range using a Typhoon 9410 PhosporImager and ImageQuant 3.3 software (Molecular Dynamics, Amersham Biosciences).
MCF-7 Proliferation and Migration Assays
MCF-7 cells (ATCC) were maintained at 60% -80% confl uence in Dulbecco's modifi ed Eagle's medium (DMEM) supplemented with 1 mM sodium pyruvate and 10% fetal calf serum at 37 °C and 5% CO 2 . To measure proliferation, 10 4 MCF-7 cells were plated in triplicate in DMEM and cultured until they reached approximately 60% confl uence. Cells were treated with or without 25 ng/mL of VEGF (Sigma, Perth, Australia) and cultured for 16 hours. Cells were then assayed for proliferation using the BrdU labeling and Detection Kit I (Roche). The percentage of positive cells was counted in a blind assay in 10 fi elds per group. Each experiment was performed three times.
For migration assays, MCF-7 cells were transfected with Sox18RaOp-expressing pcDNA3.1 and stable transfectants selected with G148 gentamicin (GIBCO-BRL, Melbourne, Australia) at 800 μ g/mL. Single colonies were expanded and tested for Sox18RaOp expression by immunohistochemistry. Stably expressing Sox18RaOp (MCF-7 Ra ) and parental cells (10 5 ) were added to the upper well of a Boyden chamber containing an 8.0-μ m-poresize polycarbonate membrane separating two 6.5-mm Transwell chambers (Costar). The upper wells were placed into the lower chambers, which contained 0.75 mL of DMEM. VEGF (50 ng/mL) was added to the upper or lower well to act as a chemoattractant. After 4 hours at 37 °C in 5% CO 2 , nonmigratory cells on the membrane surface in the upper chamber were removed with a cotton swab, and the cells that had traversed the membrane onto the lower surface were fi xed and stained with the fl uorescent nuclear stain 4 ′ -6-diamidino-2-phenylindole (DAPI) at 10 μ g/mL for 15 minutes. Membranes were mounted on glass slides, and cells in three random fi elds per slide were counted in a doubleblind assay. Three independent experiments were performed.
Immunoblot Analysis of Signaling Proteins
Cells were lysed directly into Laemmli buffer (containing 1% sodium dodecyl sulfate and 5% β -mercaptoethanol), and protein concentrations were determined by comparison to known standards by gel electrophoresis. Equal amounts of protein (10 μg) were subjected to sodium dodecyl sulfate -polyacrylamide gel electrophoresis on 10% acrylamide gels and electrophoretically transferred to nylon membranes (Hybond N+; Amersham Bio sciences). Standard immunoblot analysis was performed using rabbit polyclonal anti -α -tubulin (1 : 2000; Cell Signaling Technology, Beverly, MA), rabbit polyclonal anti -phosphohistone H1 (1 : 1000; Upstate Biotechnology, Charlottesville, VA), rabbit polyclonal anti-SAPK/JNK (1 : 1000), and rabbit polyclonal anti -phospho SAPK/JNK T183/Y185 (1 : 1000; Cell Signaling Technology). Bound antibody was detected using polyclonal goat anti-rabbit IgG conjugated to horseradish peroxidase (Jackson Laboratories), and antigen -antibody complexes were visualized using the ECL chemiluminescence reagent (Pierce, Rockford, IL).
Labeling of Actin Cytoskeleton
To visualize fi lamentous actin, MCF7 and MCF7 Ra cells were stained with Texas Red X-Phalloidin (1 : 2000; Molecular Probes, Invitrogen) according to the manufacturer's protocol. Nuclei were counterstained with DAPI (10 μ g/mL).
Statistical Analysis
Statistical signifi cance of differences between paired groups were determined using the Student's t test. Variance between multiple groups was calculated using analysis of variance. All statistical tests were two-sided, and P <.05 was considered statistically signifi cant.
R ESULTS
SOX18 Expression During Developmental and Oncogenic Vascularization
We fi rst investigated SOX18 expression during tumor angiogenesis. SOX18 protein was detected in neovascular endothelial cells in human colorectal tumors (n = 4) and in mouse melanoma allografts (n = 6), consistent with the hypothesis that SOX18 is important for tumor angiogenesis in humans ( Fig. 1, A ) .
We also found that Sox7, Sox17, and Sox18, the three members of Sox subgroup F with similar sequence and structural features ( 6 ) , were coexpressed in vascular endothelial cells during developmental angiogenesis in wild-type mice ( Fig. 1, B ) . This fi nding supports the hypothesis, based on molecular studies ( 16 , 19 ) , that the lack of overt vascular phenotype observed in Sox18 − / − mice is due to functional redundancy between these related proteins and that the Ra O p mutant form of Sox18 acts in a dominant-negative manner to interfere with the function of all three transcription factors during angiogenesis.
Allograft Tumor Growth in Mice Heterozygous for Ra O p or Null for Sox18
We next investigated whether impaired SOX18 function would inhibit the vascularization and subsequent growth of tumors. Cells from an aggressive mouse melanoma cell line (B16) were injected subcutaneously, at two posterior dorsal sites, into mice heterozygous for Ra O p (Ra O p/+ ), mice null for Sox18 (Sox18 − / − ), and wild-type mice, siblings of the Ra O p/+ cohort (n = 4 per group). Ten days after injection, tumors from the three strains of mice were noticeably different in size ( Fig. 2, A ) . After 14 days, tumors in wild-type mice were large (mean volume = 817 mm 3 , 95% CI = 643 mm 3 to 1001 mm 3 ; Fig. 1 ) , and the experiment was terminated for ethical reasons. At this time, tumors in Sox18 − / − mice were smaller (mean volume = 486 mm 3 , 95% CI = 345 mm 3 to 627 mm 3 ; P = .004; Fig. 1 ) than those in wildtype mice. Tumor growth in Ra O p/+ mice was dramatically slower than that of wild-type mice (mean volume = 233 mm 3 , 95% CI = 73 mm 3 to 119 mm 3 ; P <.001; Fig. 2 ). Tumors from Ra O p/+ mice were histologically dense, whereas those from Sox18 − / − and wild-type mice were markedly less so (data not shown). Some Ra O p/+ mutant mice bearing allograft tumors were maintained to the end of the 40-day observation period, with minimal tumor growth and no sign of morbidity.
Microvessel Density in Allograft Tumors
To establish whether impaired tumor growth was associated with a paucity of neovasculature, histologic sections of the tumors were stained using monoclonal CD31 and NG2 chondroitin antibodies to visualize endothelial cells and vascular pericytes, respectively ( 26 , 27 ) . NG2-stained pericytes are associated only with mature endothelial vasculature and as previously reported; proportionally less of this mature vasculature was observed in the tumor microenvironment ( 28 ) . However, CD31 is expressed in both tumorigenic lymph and angiogenic endothelial cells of both early and mature vasculature. Tumors from wild-type mice had abundant vasculature, whereas those from Sox18 − / − and Ra O p/+ mice had relatively smaller and sparser vessels ( Fig. 3, A ) . Counts of CD31-and NG2-positive vessels with clear lumens in the plane of the section in three separate tumors from each of the Ra O p/+ , Sox18 − / − , and wild-type mice confi rmed a dramatic reduction in microvessel numbers in Ra O p/+ and, to a lesser extent, in Sox18 − / − mice ( Fig. 3, B ) . These data, together with the known role of SOX18 in vascular development, strongly suggest that the observed tumor growth inhibition was a direct consequence of impaired microvessel development leading to dramatically reduced vasculature in the tumors.
Effect of SOX18 and Sox18RaOp on Tube Formation and Cell Migration in Human Endothelial Cells
To investigate the role of SOX18 in endothelial function during angiogenesis, we used an in vitro tube formation assay, in which HUVECs grown on a collagen matrix stimulated by the addition of phorbol myristate acetate and anti -α 2 β 1 -integrin antibody to invade the substrate and form tubular networks over 24 hours ( 29 ) . We fi rst established, using virtual northern blotting, that human Sox18 is expressed during this process and that expression of Sox18 mRNA was highest between 0.5 and 1 hour ( Fig. 4, A ) , an interval that corresponds to active migration of the HUVECs into the matrix, and lowest at 6 hours, when cell migration rates slow and endothelial tubes start to form ( 30 , 31 ) . Expression levels increased again between 6 and 24 hours, coinciding with capillary tube maturation ( Fig. 4, A and B ) .
Next, we transfected HUVECs with Sox18RaOp, the dominant-negative form of SOX18 produced in the Ra O p/+ mutant mouse. Such HUVECs showed a dramatic reduction in tube formation compared with that in cells transfected with empty vector ( Fig 4, C ) . Large continuous capillary tubes formed in the cells that were transfected with the empty vector, whereas the tubes formed in the cells transfected with Sox18RaOp were short and often failed to join up into a network.
We also assessed capillary tube formation in HUVECs in which overexpression of wild-type SOX18 was achieved by adenoviral infection. Infection effi ciencies in excess of 90% were achieved using the pAdEasy system, quantifi ed by fl uorescence-activated cell sorting analysis. Tubular networks formed and progressed more quickly in cells that overexpressed wildtype Sox18 than in vector controls, being noticeable by 3 hours in Sox18 cells ( Fig. 4, C ) compared with 4 -6 hours (data not shown) in control cells. The results of this gain-of-function assay complement both the Sox18RaOp in vitro overexpression data and the results of the in vivo loss-of-function analyses described above, and they suggest a role for SOX18 in facilitating tube formation, which in turn may be due to effects of SOX 18 on the rate of endothelial cell migration, proliferation, and/or assembly into vessels.
Effect of Sox18RaOp Expression on Migration and Proliferation In Vitro
To investigate the effect of SOX18 dysfunction on cell proliferation and migration, we established from one colony of transfected MCF-7 mammary adenocarcinoma cells a line stably expressing Sox18RaOp (MCF-7 Ra ). All cells of this clonal line expressed RaOp at similar levels (data not shown). Previous studies have established that proliferation and migration in both endothelial and MCF-7 cells occur via similar mechanisms and that MCF-7 cells express elevated levels of Sox18 ( 21 , 32 , 33 ) . MCF-7 Ra and parental MCF-7 cells were grown in the presence or absence of VEGF for 24 hours, and the rate of proliferation A ) Sox18 mRNA levels during capillary tube formation in vitro. Total RNA from adenovirus-infected HUVECs was isolated at the times (hours) shown and analyzed for Sox18 and cyclophilin A (CYCA) expression using virtual northern blot analysis. Duplicate virtual northern blots (Expt A and B) were performed. B ) RNA levels in A were quantifi ed using a phosphorimager; Sox18 mRNA levels were normalized to that of CYCA, and the fold induction was plotted over time. C ) HUVECs expressing wild-type Sox18 or empty vector ( left ) and HUVECs transiently transfected with empty vector or with a dominant-negative form of Sox18 expressing construct (RaOp) ( right ) that were induced to undergo capillary tube formation in vitro were photographed every 30 minutes. Data presented at 1.5, 3, 4, and 21 hours ( arrows , tube formation). Scale bar = 200 μ m.
was then analyzed. MCF-7 Ra cells proliferated at a slower rate than parental MCF-7 cells in the presence of VEGF (BrdU incorporation, mean = 20%, 95% CI = 15% to 25% versus mean = 41%, 95% CI = 35% to 45%; P = .013; Fig. 5, A ) .
We also carried out MTS proliferation assays using monolayer cultures of HUVECs that were transiently transfected with the Sox18RaOp expression construct. Again, we observed a substantial decrease (approximately 33%) in cell viability of HUVECs transfected with Sox18RaOp-expressing construct compared with cells transfected with empty vector (optical density at 490 nm, mean = 0.27 versus mean = 0.46; difference = 0.19, 95% CI = 0.145 to 0.235; P = .001; Fig. 5, B ) .
We next examined the effect of SOX18 on several biochemical pathways associated with cell migration and/or proliferation. Immunoblot analysis of protein extracts revealed that MCF-7 Ra and HUVECs transiently transfected with murine Sox18RaOp had lower levels of H1-histone phosphorylation than parental MCF7 cells and HUVECs transfected with empty vector, characteristic of cells accumulating in G 1 phase of the cell cycle ( Fig. 5, C ) ( 34 , 35 ) . Because JNK activity has previously been implicated in proliferative and migratory control pathways in these and other cell types ( 33 , 36 ) , we next examined levels of JNK phosphorylation. Although we observed no difference in JNK phosphorylation between MCF-7 Ra and parental cells, JNK phosphorylation was substantially reduced in HUVECs transiently transfected with Sox18RaOp compared with empty vector control subjects. These data suggest that the dominant-negative (i.e., Sox18RaOp) form of SOX18 exerts a negative effect on cell proliferation and migration. However, HUVECs may be more sensitive to the mechanism by which this interference occurs, as demonstrated by more severe disruption of the mitogen-activated protein kinase signaling pathway in HUVECs compared with that in MCF-7 cells. Although these experiments do not fully exclude the possibility that the altered behavior of the MCF-7 Ra cells was due in part to the process of selecting the clones, the similarities with the observed effects in HUVECs suggest that selection is not the case.
To further investigate the functional link between Sox18 expression and cell migration, we next examined the effect of Sox18 and Sox18RaOp in migrating cells. In Boyden chamber migration assays, we observed a decrease in MCF-7 Ra cell migration of 60% compared with parental cells in the presence of the chemoattractant VEGF ( Fig. 6, A ) . Similar results were per well and proliferation was measured at day 0 and day 3 using the MTS assay (optical density at 490 nm). The means and 95% confi dence intervals of two independent experiments performed in duplicate (n = 6 per group) are shown. *, P = .001, as determined by Student's t test. C ) Immunoblots of MCF-7 Ra and HUVECs transiently expressing Sox18RaOp and the respective control subjects using anti -phospho-Histone H, anti-phospho-JNK, and anti-JNK. Anti -α -tubulin was used as a loading control. One immunoblot (of three) is shown. Fig. 6 . Migration and cytoskeletal structure of MCF-7 cells expressing wild-type and dominant-negative SOX18. A ) MCF-7 Ra and parental cells were seeded into the upper well of a Boyden chamber in the presence or absence of 50 ng/mL vascular endothelial growth factor (VEGF). The means and 95% confi dence intervals of three experiments are shown. **, P <.001, as determined by Student's t test. B ) MCF-7 Ra or parental cells were stimulated with 50 ng/mL of VEGF for 4 hours, fi xed, and stained with DAPI and Texas Red X-phalloidin to visualize nuclear DNA and cytoskeletal actin fi bers, respectively. Arrows indicate internal cytoskeletal stress fi bers and arrowheads , the cell periphery. MCF-7 Ra cells showed reduced levels of organized actin cytoskeleton at the periphery and internally. Images from one experiment of three are shown. Bar = 10 μ m. To investigate the possible involvement of disruption to the actin cytoskeleton in the observed changes in cell migration, we compared actin assembly in MCF-7 Ra and MCF-7 cells ( 33 , 36 ) . In wild-type cells, polymerized actin was observed in a rigid cytoskeleton at the cell periphery and in parallel transcellular stress fi bers ( Fig. 6, B ) . In MCF-7 Ra cells, lower levels of actin were observed at the cell periphery and fewer actin stress fi bers formed ( Fig. 6, B ). These differences in actin organization suggest that SOX18 regulates cell migration by infl uencing actin cytoskeleton organization. This regulation may not involve a direct effect on the actin cytoskeleton; rather, it may be indicative of a role for SOX18 in regulating the expression of genes involved in cell motility and migration.
D ISCUSSION
Angiogenesis is essential for cancer progression and is one of the characteristics of metastases and poor patient prognosis. Direct angiogenesis inhibitors such as angiostatin and bevacizumab specifi cally target vascular endothelial cells, preventing them from proliferating or migrating or from avoiding cell death in response to proangiogenic signals ( 37 -39 ) . Here we have identifi ed Sox18 as a gene expressed in endothelial cells during the initial steps of tumor vascularization and demonstrate that interfering with its function inhibits blood vessel formation and subsequent tumor growth.
In this study, mice heterozygous for the dominant-negative Sox18 mutation Ra O p or null for Sox18 showed reduced tumor growth when injected with cells cultured from a mouse B16 melanoma line. The reduction in tumor size corresponded to a reduction in microvessel density. Microvessel density is strongly associated with metastatic risk and poor prognosis in most, although not all, tumor types ( 40 ) , and although microvessel density is not necessarily a good indicator of therapeutic effi cacy, a reduction in microvessel density after treatment generally leads to an improved prognosis ( 40 , 41 ) . Our observations, therefore, suggest that the ability of the host endothelial cells to respond to proangiogenic signals is perturbed in Ra O p and Sox18-null mice, resulting in fewer microvessels in the tumor and subsequent tumor growth inhibition.
We found that SOX18 also plays a role in regulating cell migration and subsequent vascular tube formation. When Sox18RaOp was overexpressed in HUVECs, tube formation was disrupted, and when SOX18 was overexpressed, tube formation was augmented, suggesting that SOX18 promotes vascularization, possibly by increasing endothelial cell migration rates. Previous studies have suggested that endothelial cells migrate into a soft matrix by using a rigid actin cytoskeletal structure, which then undergoes reversible remodeling before tubelike structures can form ( 42 ) . Extra SOX18 may promote this activity. Conversely, the forced overexpression of the dominant -negative form of Sox18 disrupts the migration of MCF-7 cells by causing a breakdown of the rigid cytoskeletal assembly, characterized by less actin at the cell periphery and fewer transcellular stress fibers. Although this disruption may not impede cell spreading, adhesion, or survival on a rigid two-dimensional surface, it may contribute to the observed compromised ability of MCF-7 Ra cells to migrate in response to a chemoattractant such as VEGF.
Also, the reduced rate of proliferation observed in both HUVECs and MCF-7 cells expressing Sox18RaOp may also contribute to the decrease in tumor microvessel density. Levels of phosphorylated histone H1 normally increase and peak as cells enter M phase, with levels of phosphorylation being lowest in G 1 phase ( 34 ) . The reduced rate of proliferation of MCF-7 Ra cells (seen via BrdU incorporation) corresponded to a decrease in the amount of phosphorylated histone H1 in these cells, suggesting that they are accumulating in G 1 phase and not dividing. Similarly, in HUVECs transiently transfected with a construct to overexpress the murine Sox18RaOp form of Sox18, a decrease in the levels of phosphorylated histone H1 was observed. Our observations imply that inhibiting SOX18 function may also restrict the number of endothelial cells present in tumor neovasculature by reducing their rate of proliferation. In accordance with this assertion, data recently reported indicate that the overexpression of SOX18 in endothelial cells may contribute to vascular cell growth in advanced human coronary atherosclerotic lesions, which can be reduced by blocking Sox18 expression in these cells ( 43 ) .
Interestingly, phosphorylation of JNK was decreased in HUVECs expressing the Sox18RaOp dominant-negative form of Sox18, but not in MCF-7 Ra cells. The inhibition of JNK phosphorylation contributes to impaired cell migration and proliferation in endothelial cells ( 36 , 44 ) . The apparent difference in the response of the two cell lines suggests that HUVECs are more sensitive to SOX18, and therefore also to the Sox18RaOp form of Sox18, signifying that HUVECs may have more angiogenic-related cofactors within their nuclei than do MCF-7 cells.
Although this work highlights Sox18 as a potential target for an antiangiogenic agent, several obstacles remain. The design of specifi c transcription factor inhibitors and their delivery to the correct cells are real challenges. Recent advances in the use of peptidomimetics, antisense oligonucleotides, and small-molecule inhibitors may provide an avenue for mimicking the ability of Sox18RaOp to interfere with Sox18, -17 and -7 activity simultaneously during tumor angiogenesis ( 45 ) . Such specifi c drug design in combination with targeted delivery systems offers real potential for exploiting Sox18 as an antiangiogenic target ( 46 ) .
Regardless of these issues, it is clear that targeting the genes involved in endothelial cell function is likely to provide important adjunct approaches to current available anticancer therapies. In particular, genes involved in the early development, differentiation, and assembly of endothelial cells into a neovasculature are likely to be of value in this context, because interfering with their function is less likely to compromise the function of existing mature vasculature. Studies in mice have shown that Sox18 is active in developing embryonic vasculature but not in mature blood vessels ( 17 ) . Here we have established that interference of SOX18 function by using a dominant-negative allele of Sox18 (Ra O p ) severely restricted tumor growth in vivo and that this inhibition coincided with decreased tumor microvessel density and reduced cell migration and proliferation in vitro. The degree of tumor inhibition is all the more remarkable given that Sox18 function is only partially compromised in heterozygous Ra O p mutant mice ( 15 ) . The inhibition of tumor growth in a mouse model, together with recent advances in targeted, systemic gene delivery to tumor neovasculature ( 46 ) , indicates that SOX18 may be a useful target for human cancer therapy.
